| Literature DB >> 28406457 |
Xiang-Rong Tian1, Yan-Qing Gao2, Xiao-Lin Tian3, Jiao Li4, Hai-Feng Tang5, Yu-Shan Li6, Hou-Wen Lin7, Zhi-Qing Ma8.
Abstract
A new sterol, (23R)-methoxycholest-5,24-dien-3β-ol (1), two new ceramides, (2S,3R,4E,8E)-2-(tetradecanoylamino)-4,8-octadecadien-l,3-diol (6) and (2S,3R,2'R,4E,8E)-2-(tetradecanoylamino)-4,8-octadecadien-l,3,2'-triol (7), together with three known sterols (2-4), a lactone (5) and two ceramides (8,9), were isolated from the marine bryozoan Cryptosula pallasiana, collected at Huang Island of China. The structures of the new compounds were elucidated by extensive spectroscopic analyses, chemical methods and quantum electronic circular dichroism (ECD) calculations. Among the isolated compounds, sterol 1 possessed a rare side chain with a methoxy group at C-23, and a double bond between C-24 and C-25. Ceramides 6 and 7 possessed 14 carbons in their long-chain fatty acid base (FAB), which were different from the normal ceramides with 16 carbons in the FAB. Moreover, compounds 5 and 8 were isolated for the first time from marine bryozoans. Compounds 1-9 were evaluated for their cytotoxicity against human tumor cell lines HL-60, Hep-G2 and SGC-7901. The results showed that lactone 5 appears to have strong cytotoxicity against the test tumor cell lines, with IC50 values from 4.12 μM to 7.32 μM, and sterol 1 displayed moderate cytotoxicity with IC50 values between 12.34 μM and 18.37 μM, while ceramides 6-9 showed weak cytotoxicity with IC50 ranging from 21.13 μM to 58.15 μM.Entities:
Keywords: Cryptosula pallasiana; ceramides; cytotoxicity; marine bryozoan; sterol
Mesh:
Substances:
Year: 2017 PMID: 28406457 PMCID: PMC5408266 DOI: 10.3390/md15040120
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–9 from marine bryozoan C. pallasiana.
Figure 2Key 1H-1H COSY and HMBC correlations of 1.
1H- and 13C-NMR (500 and 125 MHz, CDCl3) data of 1 a.
| No. | δC | δH mult., | No. | δC | δH mult., |
|---|---|---|---|---|---|
| 1 | 37.3 | α 1.86, m | 13 | 42.5 | – |
| β 1.08, m | 14 | 56.9 | 1.04, m | ||
| 2 | 31.7 | α 1.84, m | 15 | 24.3 | α 1.57, m |
| β 1.50, m | β 1.07, m | ||||
| 3 | 71.8 | 3.52, m | 16 | 28.2 | α 1.83, m |
| 4 | 42.3 | α 2.28, m | β 1.30, m | ||
| β 2.23, m | 17 | 56.8 | 1.01, m | ||
| 5 | 140.7 | – | 18 | 12.0 | 0.73, s |
| 6 | 121.7 | 5.35, t (2.5) | 19 | 19.4 | 1.00, s |
| 7 | 31.9 | α 1.50, m | 20 | 32.5 | 1.66, m |
| β 1.97, m | 21 | 18.7 | 0.95, d (5.9) | ||
| 8 | 31.9 | 1.50, m | 22 | 42.5 | α 0.92, m |
| β 1.68, m | |||||
| 9 | 50.1 | 0.93, m | 23 | 74.8 | 3.94, dt (9.3, 3.1) |
| 10 | 36.5 | – | 24 | 127.0 | 5.03, td (9.0, 2.6, 1.3) |
| 11 | 21.1 | α 1.43, m | 25 | 134.5 | – |
| β 1.49, m | 26 | 18.2 | 1.67, d (1.0) | ||
| 12 | 39.8 | α 1.16, m | 27 | 25.9 | 1.74, d (1.1) |
| β 2.03, m | 23-OCH3 | 55.7 | 3.21, s |
a Assignments based on DEPTs and HSQC.
Figure 3Key NOESY correlations () for 1.
Figure 4Experimental and calculated ECD spectra for 1.
1H- and 13C-NMR (500 and 125 MHz, CDCl3) of 6 and 7 a.
| No. | 6 | 7 | ||
|---|---|---|---|---|
| δC | δH mult., | δC | δH mult., | |
| 1 | 62.5 | 3.70, dd (11.3, 3.3) | 62.2 | 3.72, dd (11.0, 3.0) |
| 3.90, m | 3.89, m | |||
| 2 | 54.5 | 3.95, dd (11.3, 3.5) | 54.4 | 3.92, br d (11.0) |
| 3 | 74.7 | 4.32, m | 74.7 | 4.30, m |
| 4 | 129.2 | 5.54, dd (15.4, 6.4) | 129.2 | 5.52, dd (15.5, 6.0) |
| 5 | 133.6 | 5.78, dt (15.4, 6.6) | 133.5 | 5.75, dt (15.5, 6.1) |
| 6 | 32.3 | 1.97, q (6.7) | 32.4 | 1.96, q (6.5) |
| 7 | 32.1 | 2.12, m | 32.2 | 2.11, m |
| 8 | 131.4 | 5.42, dt (15.2, 6.3) | 131.3 | 5.41, m |
| 9 | 129.0 | 5.37, dt (15.2, 6.4) | 129.0 | 5.38, m |
| 10 | 32.6 | 2.08, m | 32.2 | 2.07, m |
| 11~15 | 29.2–29.7 | 1.26, br s | 29.2–29.7 | 1.26, br s |
| 16 | 31.9 | 1.26, br s | 32.0 | 1.26, br s |
| 17 | 22.7 | 1.26, br s | 22.7 | 1.26, br s |
| 18 | 14.1 | 0.88, t (6.8) | 14.1 | 0.87, t (7.0) |
| 1′ | 174.0 | – | 175.0 | – |
| 2′ | 36.9 | 2.23, t (7.5) | 72.4 | 4.12, dd (7.8, 3.4) |
| 3′ | 25.8 | 1.64, m | 34.8 | 2.16, t (3.3) |
| 4′ | 29.2–29.7 | 1.26, br s | 31.8 | 1.26, br s |
| 5′ | 29.2–29.7 | 1.26, br s | 25.1 | 1.63, m |
| 6′~11′ | 29.2–29.7 | 1.26, br s | 29.2–29.7 | 1.26, br s |
| 12′ | 31.9 | 1.26, br s | 31.9 | 1.26, br s |
| 13′ | 22.7 | 1.26, br s | 22.7 | 1.26, br s |
| 14′ | 14.1 | 0.88, t (6.8) | 14.1 | 0.87, t (7.0) |
| NH | – | 6.25, d (7.5) | – | 6.20, d (7.8) |
a Assignments based on DEPTs and HSQC.
Figure 5Key 1H-1H COSY and HMBC correlations (A), and main ESI-MS fragment ions (B) of 6. (a positive fragment ions; b negative fragment ions).
Figure 6Key 1H-1H COSY and HMBC correlations (A), and main ESI-MS fragments (B) of 7.
Cytotoxicity of compounds 1–9 against HL-60, HepG2 and SGC7901 tumor cell lines in vitro (IC50, μM) .
| Compound | HL-60 | HepG-2 | SGC-7901 |
|---|---|---|---|
| 1 | 17.64 ± 0.32 | 12.34 ± 0.12 | 18.37 ± 0.17 |
| 2 | >100 | >100 | >100 |
| 3 | >100 | >100 | >100 |
| 4 | >100 | >100 | >100 |
| 5 | 6.29 ± 0.11 | 4.12 ± 0.15 | 7.32 ± 0.26 |
| 6 | 32.26 ± 0.23 | 26.69 ± 0.21 | 27.14 ± 0.30 |
| 7 | 25.32 ± 0.17 | 21.13 ± 0.13 | 22.74 ± 0.16 |
| 8 | 35.72 ± 0.36 | 28.53 ± 0.24 | 30.31 ± 0.14 |
| 9 | 58.15 ± 0.28 | 46.21 ± 0.17 | 45.79 ± 0.12 |
| Adriamycin b | 2.51 ± 0.14 | 2.73 ± 0.23 | 2.65 ± 0.17 |
a IC50 values are means from three independent experiments in which each compound concentration was tested in three replicate wells; b Adriamycin as a positive control.